PHA/NHLBI K08/K23 Award Winner 2011

Edda Frauke Spiekerkoetter, MD

Edda Spiekerkoetter, MD

Division of Pulmonary and Critical Care Medicine
Department of Medicine
Stanford University Medical Center
"Modulating BMPRII signaling in Pulmonary Arterial Hypertension"
NHLBI Mentored Clinical Scientist Development Award (K08)
Term: September 1, 2011 – August 31, 2016

Summary of Research Project:

Modulating BMPRII signaling in Pulmonary Arterial Hypertension

Our goal is to find novel ways to treat pulmonary arterial hypertension (PAH). The approach we are pursuing is to increase signaling through the bone morphogenetic protein receptor (BMPR)-2.

Seventy percent of patients with familial and 20% of patients with idiopathic pulmonary arterial hypertension (IPAH) carry a mutation in one of the two BMPR2 alleles that leads to a dysfunctional signaling via this receptor. However, the penetrance i.e., the propensity of individuals with a mutation, to develop PAH is less than 20%. Recent studies have shown that reduced levels of the normal BMPR2 allele distinguish affected from non-affected family members. Even PAH associated with other diseases (APAH) can be accompanied by reduced protein expression of BMPR2. Therefore it seems that the level of signaling through the BMPR2 receptor is important in PAH. A novel approach to the prevention and treatment of pulmonary hypertension could be restoration of BMPR2 signaling.

We are pursuing 2 strategies, the first of which will be to modulate the levels of relevant micro-RNAs that impact BMPR2 expression by using micro RNA mimics or antagomirs. As a second strategy, we are screening pharmacologically active compounds and small molecules that could enhance signaling from the BMPR2 receptor.

We have developed a High Throughput Screen using 3600 FDA approved drugs and pharmacologically active compounds. With this technique, i8/25/11n addition to “hits” that enhance BMP signaling, we can also identify molecules and drugs that inhibit signaling from the BMPR2 receptor and therefore could be harmful in IPAH patients and non-affected family members with already compromised BMPR2 expression. We have already identified one compound, the immunosuppressive drug FK-506 (Tacrolimus), as having the propensity to increase BMP signaling. We validated these findings in cell culture and animal models of experimental pulmonary hypertension. Low dose FK-506 prevents and reverses established pulmonary hypertension in 3 different animal models of pulmonary hypertension (mice, rats). Given that FK-506 is an FDA-approved drug with a known side-effect profile and given our observation that even a very low dose of FK-506 can activate BMPR2 signaling, this drug seems to be very promising to test in the clinical setting.

Our research is very translational in nature. We hope to identify more compounds that will increase BMPR2 signaling and to develop novel approaches such as the use of microRNAs to influence BMPR2 expression with the ultimate goal to find ways how to arrest and prevent the development of pulmonary arterial hypertension.

CURRICULUM VITAE

Edda Frauke Spiekerkoetter, MD
Division of Pulmonary and Critical Care Medicine
Department of Medicine
Stanford University Medical Center

Education/Training:

Dec. 1995

MD Thesis: Magna cum laude
Passive smoking exposure in school aged children in Southwest Germany University of Freiburg, Department of pediatrics. Germany. Mentor: Prof J Forster.

April 1991 - Dec. 1995 Medicine, Albert-Ludwigs-University Medical School, Freiburg, Germany
Degree: MD
Sept 1988 - Mar. 1991  Medicine, Eberhardt-Karls University of Tuebingen, Germany
Sept. 1986 - Sept.
1988
Biology, Eberhardt-Karls University of Tuebingen, Germany,
Degree: Bachelor of Science

Licensure and Certification:

Sept 2009 Full Privileges in Pulmonary and Critical Care Medicine, Stanford University Medical Center
Aug 2009 Medical License, Medical Board of California
Sept 2006 Educational Commission for Foreign Medical Graduates (ECFMG) certification
USMLE Step1 July 2006, USMLE Step 2 CK Aug 2006, USMLE 2 CS Sept 2006, USMLE Step 3 Jul 2007
Aug 2002 Board Certification Internal Medicine, Germany

Positions and Employment Professional activity:

Sept 2009 - present

K12 Scholar ”Stanford career development program in Genetics and Genomics of pulmonary diseases”.
Director: Dr. Mark Krasnow
Mentors: Dres. Marlene Rabinovitch and Phil Beachy
Project: Modulating BMPRII signaling in Pulmonary Arterial Hypertension

Sept. 2009 - present Instructor of Medicine and staff attending physician, Department of Pulmonary and Critical Care, Adult Pulmonary Hypertension Service, Stanford University
July 2008 - June 2009 Critical Care Fellow, Stanford University Hospital and Clinics, Stanford
July 2007 - June 2008 Pulmonary and Critical Care Fellow, Stanford University Hospital and Clinics, Stanford
Feb. 2007 - May 2007 Pulmonary Hypertension Database management, Stanford University
Oct. 2002 - Jan. 2007 Postdoctoral research fellow, Department: Pediatric Cardiology,

Prof. Dr. M. Rabinovitch, Stanford University Medical School, Stanford

March 1996 - Sept 2002 Residency: Internal Medicine and

Fellowship: Pulmonary and Critical Care at
Medical School Hannover, Department of Respiratory and Critical Care Medicine. Director: Prof. Dr. med. H. Fabel
Including: 1 year: Lung transplant fellow
1/2 year: Pulmonary Hypertension fellow (outpatients, right-heart catheterization, clinical trials of new therapeutic drugs for pulmonary hypertension)

Teaching:

Stanford University/Stanford Medical Center:

Sept 2010 - present

Organization of a 2-weekly Clinical Topics Series in Pulmonary Hypertension

2006 - present Lecturer in Cardiovascular and Pulmonary Science Seminar (Med 223, Cardiovascular Pulmonary Research Scholarly Concentration for Medical Students)
2005 - present Supervision of laboratory projects of undergraduates and summer students
2005-2006 Katie Lynn Pricola – Medical Student

Topic: SDF-1 and Pulmonary Hypertension

2006 Alexandra Bruneau - Visiting Researcher, France

Topic: Measurement of elastase activity in mice after murine HV-68 infection

2010 Leila Haghighat – undergraduate UCSD
Topic: MiR21 expression in PAECs from patients with pulmonary hypertension and healthy controls
2010 Roxanna Haghighat – summer student

Topic: Id-1 expression and Smad signalling in PAECs from patients with pulmonary hypertension and healthy controls

July 2007 - June 2009 Lectures on ICU related topics for residents, interns and medical student
Medical School Hannover:
March 1996 - Sept 1997 Internal Medicine (School of Nursing)
March 1996 - Sept 2002 Medical Students: Practice of examination and history taking
Jan 2000 - Sept 2002

Lectures: Pathophysiology of the lungs; Practical Pneumology
Supervision of medical students working on their doctoral thesis in the field of respiratory medicine, pulmonary hypertension

   

Technical Experience:

Surgical techniques:
Closed chest vascular and heart catheterization (in mice, rats)
Heart-Lung Preparation: performed in mice and rats.
Hemodynamic measurements: Right ventricular systolic pressure and mean arterial pressure measurements, cardiac functions measurements performed in mice and rats.
Implantation of subcutaneous infusion pumps in mice and rats
Endotracheal instillation of medication in mice

Molecular Biology:
PCR, quantitative RT-PCR, genomic DNA isolation, RNA purification, Western blotting, Southern blotting, Liposomal and retroviral transfection of primary cells, siRNA, miRNA mimics and antagomirs, DNA microarray

Cell Culture:
Culture of human pulmonary artery smooth muscle and endothelial cells. Organ culture of human and mouse lung.

Cell Biology Assays:
Migration assays using Boyden chambers, PCNA , TUNEL and Proliferation assays.

Microscopy:
Bright Field, Fluorescence, and Confocal microscopy.

Histology:
Paraffin embedding and hemotoxylin/eosin and Hart’s staining. Immunohistochemistry and immunofluorescence. Assessment of morphological parameters in pulmonary arteries, lungs, and hearts of mice.

Micro CT:
Scanning and reconstructing of barium infused lungs in mice.

Biochemical assays:
Elastase activity Assay

Development of a High Throughput Screen of FDA approved drugs and Small molecules to test for compounds that activate or inhibit BMPRII signaling using as luciferase reporter system.

Awards:

Sept 2009

Career Development Award - K12 – NIH5K12HL089989

March 2003 – Feb 2005

Postdoctoral Research Fellowship of the Pulmonary Hypertension Association (PHA) and American Heart Association (AHA) for research on pulmonary hypertension

Professional Societies:

Member ATS (1997 – present)
Member AHA (2004- present)
Fellow Pulmonary Vascular Research Institute (2009 – present)
Faculty, Vera Moulton Wall Center For Pulmonary Vascular Disease (2009- present)
Member, Stanford Cardiovascular Institute (2009- present)

Languages:

fluency: English, German
basic knowledge: French

Publications:

Peer-Reviewed Publications:

Kim YM, Haghighat L, Spiekerkoetter E, Sawada H, Alvira CM, Wang L, Acharya S, Rodriguez-Colon G, Orton A, Zhao M, Rabinovitch M. Neutrophil Elastase Is Produced by Pulmonary Artery Smooth Muscle Cells and Is Linked to Neointimal Lesions. Am J Pathol. 2011 Jul 14. [Epub ahead of print]

Perez VA, Ali Z, Alastalo TP, Ikeno F, Sawada H, Lai YJ, Kleisli T, Spiekerkoetter E, Qu X, Rubinos LH, Ashley E, Amieva M, Dedhar S, Rabinovitch M. BMP promotes motility and represses growth of smooth muscle cells by activation of tandem Wnt pathways. J Cell Biol. 2011 Jan 10;192(1): 171-88

Spiekerkoetter E, Guignabert C, de Jesus Perez V, Alastalo T-P, Powers JM, Wang L, Lawrie A, Ambartsumian A, Schmidt AM, Berryman M, Ashley RH, Rabinovitch M. S100A4 and BMP-2 Co-Dependently Induce Vascular Smooth Muscle Cell Migration via pERK and Chloride Intracellular Channel 4 (CLIC4). Circ Res. 2009 Sep 25;105(7): 639-47

Spiekerkoetter E, Alvira CM, Kim Y-M, Bruneau A, Pricola KL, Wang L, Ambartsumian N, Rabinovitch M. Reactivation of gHV68 Induces Neointimal Lesions in Pulmonary Arteries of S100A4/Mts1 Over-expressing Mice in Association with Degradation of Elastin. Am J Physiol Lung Cell Mol Physiol. 2008 Feb;294(2):L276-89.

Hoeper MM, Seyfarth HJ, Hoeffken G, Wirtz H, Spiekerkoetter E, Pletz MW, Welte T, Halank M. Experience with inhaled iloprost and bosentan in portopulmonary hyper-tension. Eur Respir J. 2007 Dec;30(6):1096-102.

Hoeper MM, Markevych I, Spiekerkoetter E, Welte T, Niedermeyer J. Goal- oriented Treatment and Combination therapy for Pulmonary Arterial Hypertension. Eur Resp J 2005 Nov;26(5):858-63.

Spiekerkoetter E, Lawrie A, Merklinger S, Ambartsumian N, Lukanidin E, Schmidt AM, Rabinovitch M. Mts1/S100A4 stimulates human pulmonary artery smooth muscle cell migration through multiple signaling pathways. Chest. 2005 Dec; 128 (6 Suppl):577S.

Merklinger SL, Wagner RA, Spiekerkoetter E, Hinek A, Knutsen RH, Kabir MG, Desai K, Hacker S, Wang L, Cann GM, Ambartsumian NS, Lukanidin E, Bernstein D, Husain M, Mecham RP, Starcher B, Yanagisawa H, Rabinovitch M. Increased Fibulin-5 and Elastin in S100A4/Mts1 Mice with Pulmonary Hypertension. Circ Res. 2005 Sep 16;97(6):596-604. Epub 2005 Aug 18.

Lawrie A, Spiekerkoetter E, Martinez E, Ambartsumian N, Sheward WJ, MacLean MR, Hramar AJ, Schmidt AM, Lukanidin E, Rabinovitch M. Interdependent Serotonin Transporter and Receptor pathways regulate S100A4/Mts1, a gene associated with cancer and vascular disease. Circ Res. 2005 Aug 5;97(3):227-35.

MM Hoeper, Taha N, Bekjarova R, Gatzke R, Spiekerkoetter E. Bosentan treatment in patients with primary pulmonary hypertension receiving nonparental prostanoids. Eur Respir J 2003;22:330-334.

Spiekerkoetter Edda, Helmut Fabel, Marius M. Hoeper. Effects of inhaled sabutamol in primary pulmonary hypertension. Eur Resp J. 2002 Sept;20(3):524-8

Hoeper MM, Spiekerkoetter E, Westerkamp V, Gatzke R, Fabel H. Intravenous iloprost for treatment failure of aerolized iloprost in pulmonary arterial hypertension. Eur Respir J. 2002 Aug;20(2):339-43.

Hoeper MM, Schwarze M, Ehlerding S, Adler-Schuermeyer A, Spiekerkoetter E, Niedermeyer J, Hamm M, Fabel H. Long-term treatment of primary pulmonary hypertension with inhaled iloprost. Pneumologie, 2001 Jan; 55(1):38-43.

Hoeper MM, Spiekerkoetter E, Fabel H. Aerolized iloprost for Primary Pulmonary Hypertension. Letter to the editor. N.Engl J. Med. 2000 Nov 9; 343 (19): 1421-1422.

Hoeper MM, Schwarze M, Ehlerding S, Adler-Schuermeyer A, Spiekerkoetter E, Niedermeyer J, Hamm M, Fabel H. Long-term treatment of primary pulmonary hypertension with aerolized iloprost, a prostacyclin analogue. N Engl J Med. 2000 Jun 22; 342(25): 1866-77.

Hoffmeyer F, Hoeper MM, Spiekerkotter E, Harringer W, Haverich A, Fabel H, Niedermeyer J. Azathioprine withdrawal in stable lung and heart/lung recipients receiving cyclosporine-based immunosuppression. Transplantation. 2000 Aug 15; 70(3): 522-5.

Spiekerkoetter E, Krug N, Hoeper M, Wiebe K, Hamm M, Harringer W, Haverich A, Fabel H. Prevalence of malignancies after lung transplantation. Tranplant Proc. 1998 Jun; 30(4):1523-4.

Henschen M, Frischer T, Pracht T, Spiekerkotter E, Karmaus W, Meinert R, Lehnert W, Werle E, Kuehr J. The internal dose of passive smoking at home depends on the size of the dwelling. Environ Res. 1997 Jan; 72(1): 65-71.

Peer Reviewed Publications - Submitted

Zamanian RT, Spiekerkoetter E, Lawrie A, Ambartsumian N, Gould M, Doyle R, Rabinovitch M. S100A4/Mts1 as a Biomarker for Pulmonary Arterial Hypertension.

Sawada H, Saito T, Alastalo TP, Glotzbach JP, Chan R, Haghighat L, Fuchs G, Januszyk M, Lai YL, Perez V, Kim J-M, Wang L, Spiekerkoetter E, Gurtner G, Sarnow P and Marlene Rabinovitch. Reduced BMPR-II Induces GM-CSF Translation and Macrophage Recruitment in Humans and Mice, Exacerbating Pulmonary Hypertension

Reviews:

E. Spiekerkoetter, J Niedermeyer, MM Hoeper. Die pulmonale arterielle Hypertonie. Internist. Praxis 2004; 44:1-14.

E. Spiekerkoetter, M Hoeper. New Therapies in pulmonary arterial hypertension. Estratto da Minerva Pneumologica 2002;41 (4):127-136.

Spiekerkoetter Edda, Helmut Fabel, Marius M. Hoeper. Behandlung der schweren pulmonalen Hypertonie. Deutsches Ärzteblatt, 2001 Aug; 98(33): 1697-1701.

Book Chapters:

Cissarek et al: Gefaessmedizin: Therapie und Praxis. Spiekerkoetter Edda Kapitel: Die akute Lungenembolie und pulmonale arterielle Hypertonie. ABW Wissenschaftsverlag, Berlin. 2009

Cissarek et al: Vascular Medicine: Therapy And Practice. Spiekerkoetter Edda: Chapter: Acute pulmonary embolism and pulmonary Arterial Hypertension. Mcgraw-hill Professional Publishing 2010.

Abstracts:

E Spiekerkoetter, Haghighat L, Haghighat R, Sawada H, Saito T, Wang L, de Jesus Perez V, ten Dijke P, El-Bizri N, Solow-Cordero D, Beachy PA, Rabinovitch M. FK-506 (Tacrolimus), identified in a High Throughput Screen to Increase BMPRII Signaling, Prevents Pulmonary Arterial Hypertension (PAH) in Mice with Endothelial BMPRII Deletion. Talk in Mini-Symposium, ATS 2011 Denver.

E Spiekerkoetter, A Hsi, J Liu, V de Jesus Perez, K Kudelko, R Zamanian. Reassessing vasoreactivity in patients with pulmonary arterial hypertension (PAH) over time shows both, loss as well as gain in vasoreactivity . Poster ATS 2011 Denver.

Y.-M. Kim, H. Sawada, C.M. Alvira, E. Spiekerkoetter, L. Wang, M. Rabinovitch. Neutrophil elastase is the endogenous vascular elastase (EVE) produced by pulmonary artery smooth muscle cells in clinical and experimental pulmonary vascular disease. Am J Respir Crit Care Med 181;2010:A4023

E. Spiekerkoetter, T-P. Alastalo, H. Sawada, Y-M Kim, V. de Jesus Perez, L. Wang, M. Rabinovitch. Micro RNA 21 (miR-21) is a regulator of Bone Morphogenetic Protein Receptor II in patients with pulmonary hypertension. Am J Respir Crit Care Med 181; 2010:A5226

S. Snook, K. Kudelko, E. Spiekerkoetter, F. Haddad, R.T. Zamanian. Characterization of Patients with Drugs and Toxins Associated Pulmonary Arterial Hypertension: A Clinical and Outcomes Perspective. American Thoracic Society (ATS) conference 2009, San Diego. Proceedings of the American Thoracic Society 2009. A4923

Y-M Kim, E. Spiekerkoetter, M Rabinovitch. Murine gamma herpes virus-68 infection induces pulmonary vascular disease in S100A4 overexpressing mice associated with elastase activity and altered microRNA expression. AHA conference 2008, New Orleans, USA.

E. Spiekerkoetter, R. Zamanian, Y-M. Kim, T. Kleisli, J.L. Faul and M. Rabinovitch. The Elastase Inhibitor Elafin induces Regression of Neointima in an Organ Culture Model of Lungs of Patients with Pulmonary Arterial Hypertension (PAH). American Thoracic Sociey (ATS) conference 2008 Toronto, Canada.

E Spiekerkoetter, CM Alvira, A Bruneau, M Blackman, HW Virgin IV, N Ambartsumian, M Rabinovitch. A Herpes Virus Infection (MHV-68) Induces Hightened Elastase Activity and Elastin Peptides, Promoting Pulmonary Vascular Disease (PVD) in mice. Poster at the American Thoracic Society (ATS) conference 2007, San Francisco, CA

VA de Jesus Perez, G Hansmann, E Spiekerkoetter, M Rabinovitch. Cross-Talk between Bone Morphogenetic Protein (BMP) and Wingless (Wnt) may regulate common functions in Pulmonary artery (PA) smooth muscle (SMC) and endothelial cells (EC) Poster Discussion at American Thoracic Society (ATS) conference 2006, San Diego, CA, USA

E Spiekerkoetter, N Ambartsumian, MA Blackman, ES Mocarski, M Rabinovitch. Gamma Murine Herpes Virus (MHV)-68 induces severe obstructive pulmonary vascular disease (PVD) in mice overexpressing S100A4/Mts1. Poster Discussion at the American Thoracic Society (ATS) conference 2006, San Diego, CA, USA.

E. Spiekerkoetter, L Wang, N Ambartsumian, AM Schmidt, M Rabinovitch. S100A4/Mts1 mediated phospho ERK and BMP2 induced Chloride Intracellular Channel 4 (CLIC4) produce codependent migration of human Pulmonary Artery Smooth Muscle Cells (hPASMCS) American Society of Cell Biology, SF, 2005 (abstract 2424).

E Spiekerkoetter, A Lawrie, N Ambartsumian, E Lukanidin, AM Schmidt, M Rabinovitch. Interdependent S100A4/Mts1 and BMP2 signaling in human pulmonary artery smooth muscle cell (hPASMC) migration. Proceedings of the American Thoracic Society. Vol 2, 2005. A 723.

E Spiekerkoetter, SL Merklinger, A Lawrie, N Ambartsumian , E Lukanidin , M Rabinovitch. Combined environmental stimuli, d-fenfluramine and hypoxia, induce severe pulmonary hypertension in S100A4/Mts1-overexpressing mice that are prone to develop pulmonary vascular obliterative disease (PVOD) Circulation 2004 : Suppl 110 (17) A81.

E. Spiekerkoetter, Allan Lawrie, Sandra Merklinger, Noona Ambartsumian, Eugene Lukanidin, Ann –Marie-Schmidt, Marlene Rabinovitch. Crosstalk between the Bone Morphogenetic Protein Receptor II (BMPR-II) and Mts1, a novel gene in Pulmonary Hypertension. Aspen Lung conference, Aspen, Colorado June, 8-12 2004.

E Spiekerkoetter, S Merklinger, N El-Bizri, N Ambartsumian, MA Matthay, M Rabinovitch. In S100 A4/Mts1 overexpressing mice that are prone to pulmonary hypertension an inflammatory stimulus with Bleomycin alone fails to trigger pulmonary vascular obliterative disease. Am J Resp Crit Care 2004; 169 (7) A 400.

E Spiekerkoetter, Noona Ambartsumian, Eugene Lukanidin, Ann-Marie Schmidt, Marlene Rabinovitch. S100A4/Mts1 stimulates human pulmonary artery smooth muscle cell (hPASMC) migration through multiple signaling pathways. Accepted at the North American Vascular Biology Organisation (NAVBO) Meeting, Asilomar, CA, Feb 2004

S Nikkho, W Seeger, J Behr, M Borst, R Ewert, A Ghofrani, R Hetzer, M Hoeper, A Meyer, H Siedentrop, E Spiekerkoetter, H Wilkens, J Winkler, H Olschewski . Two-Year Survival in Patients with Pulmonary Hypertension Inhaling Iloprost. Am J Resp Crit Care Med 2003;167 (7) A275

E Spiekerkoetter, V Westerkamp, M Kreutz, H Fabel, A Haverich, J Niedermeyer. Malignancies after Lung- and Heart-Lungtransplantation – a single center study over a 12-year period. Am J Resp Crit Care Med 2003;167 (7) A248

J Behr, R Baumgartner, M Borst, R Ewert, A Ghofrani, M Hoeper, A Meyer, S Nikkho, H Olschwewski, S Singer, E Spiekerkoetter, H Wilkens, J Winkler, W Seeger. Consistency of the acute hemodynamic response to inhaled iloprost in pulmonary hypertension patients treated long-term with iloprost aerosol. Eur Resp J 2001:Volume 18, Suppl 33, 323s.

MM Hoeper, Ehlerding S, Schwarze M, Spiekerkoetter E, Fabel H. Primary pulmonary hypertension, hyperuricemia and renal function. Eur Resp J 2001: Volume 18: Suppl 33, 415s.

MM Hoeper, E Spiekerkoetter, N Galie, R Ewert, J Behr, D Wiedemann, H Olschewski, R Barst. Outcome after cardiopulmonary resuscitation in pulmonary arterial hypertension. Am J Resp Crit Care Med 2001;163: Suppl May.

E Spiekerkoetter, MM Hoeper, H Fabel. Hämodynamische Akuteffecte von Salbutamol-Dosieraerosol bei primär pulmonaler Hypertonie (PPH). Pneumologie 2001:55;S10.

MM Hoeper, E Spiekerkoetter, H Fabel. Geschlechtsspezifische Unterschiede in der Reaktion gegenüber Vasodilatantien bei primär pulmonaler Hypertonie (PPH). Pneumologie 2001:55;S10.

E Spiekerkoetter, A Schulz, M Klocke, E Meissner, J Niedermeyer, H Fabel, MM Hoeper. Acute effects of aerolized iloprost in pulmonary hypertension secondary to pulmonary fibrosis. Eur Resp J 2000 ; Suppl Sept.

J Niedermeyer, J Hohlfeld, E Spiekerkotter, C Wiebe, W Harringer, M Hamm, H Fabel. Longterm effects of methotrexate in bronchiolitis obliterans following lung and heart-lung transplantation. Eur Resp J 1998 ; Suppl Sept.

Oral presentations:

E Spiekerkoetter, L Wang, R Zamanian, N Ambartsumian, AM Schmidt, E Lukanidin, M Rabinovitch. Chloride intracellular channel 4 (CLIC4), a novel downstream target of Bone Morphogenetic Protein Receptor II (BMPR-II) in human pulmonary artery smooth muscle cell (PASMC) migration. Oral presentation at the American Heart Association (AHA) conference 2005, Dallas, TX.

E Spiekerkoetter, A Lawrie, SL Merklinger, M Rabinovitch. Mts1, a novel gene in the pathogenesis of pulmonary hypertension, induces migration of human Pulmonary Artery Smooth muscle cells via the Receptor for Advanced Glycation end products (RAGE). Oral Presentation at the American Heart Association (AHA) Conference 2003, Orlando, FL.

E Spiekerkoetter, MM Hoeper, H Fabel. Acute hemodynamic effects of salbutamol aerosol in patients with primary pulmonary hypertension. Oral presentation at the American Thoracic Society (ATS) conference 2001, San Francisco, CA.

Research Support

Future Research support:

09/01/2011 - 08/31/2016

1K08HL107450-01: Modulating BMPRII Signaling in Pulmonary Arterial Hypertension
Role on Project: PI

Ongoing Research Support:

09/2009 – 08/2011

K12 Career Development Program In Genetics and Genomics of Pulmonary Diseases:
Director Prof. M Krasnow, Co-director Prof. M Rabinovitch
“Development of High-Throughput Screen of drugs that modulates bone morphogenetic protein receptor II “
Role on Project: Trainee

01/2006- Present

CMREF – Pulmonary Hypertension Breakthrough Initiative (UL1RR024986)
Stanford IPAH Transplant and Preparation Center
Role on project: Co-Investigator

05/2007-Present

REVEAL Registry™:
“A Registry to Evaluate Early and Long-term Pulmonary Arterial Hypertension Disease Management”
Role on Project: Co-Investigator

Completed Research Support:

2003 – 2005

Pulmonary Hypertension Association and AHA postdoctoral research fellowship award
“Stromal Derived factor modulates homing and differentiation of stem cells in pulmonary hypertension”
Role in Project: PI

     

FacebookGoogle +TwitterLinkedInPinterestInstagramYouTubeBloggerFeedsPHAware Download our App

The information provided on the PHA website is provided for general information only. It is not intended as legal, medical or other professional advice, and should not be relied upon as a substitute for consultations with qualified professionals who are familiar with your individual needs.

801 Roeder Road, Ste. 1000, Silver Spring, MD 20910   Patient-to-Patient Support Line: 1-800-748-7274
Webmaster@PHAssociation.org
    Privacy Policy   Virtual Tour of Website    Provide Feedback & Report Bugs

Designed by Matrix Group International, Inc.® | © 2014 Pulmonary Hypertension Association. All Rights Reserved.

NORD

The National Organization for Rare Disorders (NORD) awarded PHA the Abbey S. Meyers Leadership Award in 2012 for outstanding service to PHA members in advocacy, education and other key areas.